Leishmania amazonensis is a protozoan parasite that causes leishmaniasis, a neglected tropical disease that affects millions of people worldwide. The soluble promastigote surface antigen (PSA) is a family of glycoproteins that are found on the surface of the promastigote stage of the parasite.

PSA antigens are known to be involved in the pathogenesis of leishmaniasis, and different PSA isoforms have been identified in L. amazonensis, including PSA-32S, PSA-25S, PSA-12S, PSA-34S, and PSA-31S. These PSA antigens have been shown to elicit a strong humoral immune response in infected individuals and experimental animals.

PSA-32S, PSA-25S, PSA-12S, PSA-34S, and PSA-31S are potential targets for the development of diagnostic tools and vaccines against leishmaniasis. Studying these antigens may lead to a better understanding of the immunological mechanisms involved in the host-parasite interaction and aid in the development of effective strategies to control leishmaniasis.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

Leishmania amazonensis cDNA and recombinant antigens can be used in a variety of settings. The cDNA can be used in research settings to study the genetic and molecular basis of the disease. It can also be used to create vaccines and therapeutic proteins. Recombinant antigens can also be used to create diagnostic tests and to develop vaccines and drug therapies. Additionally, cDNA and recombinant antigens can be used to identify new drug targets for the development of new drugs to treat leishmaniasis.